Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.

JS Patton, PM Peters, J McCabe… - The Journal of …, 1987 - Am Soc Clin Investig
JS Patton, PM Peters, J McCabe, D Crase, S Hansen, AB Chen, D Liggitt
The Journal of clinical investigation, 1987Am Soc Clin Investig
Treatment of healthy rats and mice with a single intravenous injection of recombinant human
tumor necrosis factor-alpha (rHuTNF-alpha) caused a dose-dependent gastrointestinal
inflammation. Within 30 min gastric emptying was blocked and tissue edema occurred in the
small and large intestine. In the cecum hemorrhage occurred after 4 h at doses greater than
or equal to 250 micrograms/kg. The cecum exhibited an acute inflammatory response
following rHuTNF-alpha treatment similar to that seen in tumor necrosis at the same dose …
Treatment of healthy rats and mice with a single intravenous injection of recombinant human tumor necrosis factor-alpha (rHuTNF-alpha) caused a dose-dependent gastrointestinal inflammation. Within 30 min gastric emptying was blocked and tissue edema occurred in the small and large intestine. In the cecum hemorrhage occurred after 4 h at doses greater than or equal to 250 micrograms/kg. The cecum exhibited an acute inflammatory response following rHuTNF-alpha treatment similar to that seen in tumor necrosis at the same dose. The vascular endothelium became swollen, increased numbers of neutrophils and other leukocytes attached to and penetrated the endothelium, and finally hemorrhage occurred. Treatment of rats with daily injections of rHuTNF-alpha (250 micrograms/kg per d) for 3 wk failed to produce cachexia. Within 24-48 h rats became resistant to the hemorrhagic effect of rHuTNF-alpha, however, the cytokine still caused a transitory block of gastric emptying after 10 d of treatment. Treatment at 5- or 10-d intervals produced results similar to the initial injection. These results suggest that maximum hemorrhagic response will occur when rHuTNF-alpha is administered at intervals of 5-10 d rather than daily.
Images
The Journal of Clinical Investigation